Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its target price lowered by Guggenheim from $12.00 to $8.00 in a report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a report on Monday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Stock Down 12.2 %

NASDAQ:ZNTL opened at $3.47 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The firm’s fifty day simple moving average is $3.42 and its 200-day simple moving average is $5.38. The stock has a market cap of $247.27 million, a PE ratio of -1.39 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. Equities analysts anticipate that Zentalis Pharmaceuticals will post -2.76 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the period. XTX Topco Ltd boosted its position in shares of Zentalis Pharmaceuticals by 8.7% in the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after acquiring an additional 15,597 shares during the last quarter. Quarry LP purchased a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $55,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Finally, Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals during the third quarter worth approximately $37,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.